Rhythm Pharmaceuticals completes $21M Series A equity financing
March 17, 2016
Mr. Henderson stated, "We are very excited about the programs we have licensed from Ipsen, and we are grateful for the support we have received from the Ipsen team."
"Peptides have tremendous potential for treating metabolic disorders since they can achieve high selectivity for complex metabolic pathways," said MPM Managing Director Steven St. Peter, M.D.
"Rhythm hopes to transform these important discoveries into valuable treatments to address unmet needs in obesity, diabetes, and other metabolic diseases," said NEA Partner Ed Mathers.
SOURCE Rhythm Pharmaceuticals